Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

South Korea’s Celltrion (Kosdaq: 068270) has announced the US launch of Steqeyma (ustekinumab-stba), a biosimilar to Stelara ...

Trulicity is a type of biologic drug. To find out whether Ozempic or Trulicity is available as a generic or biosimilar, see the list below. The Food and Drug Administration (FDA) approves ...

Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite ...

That changed when CVS Health removed Humira from its list of covered drugs and more patients switched to a biosimilar in three weeks than had in the prior 15 months. CVS, which owns a pharmacy benefit ...

Celltrion’s Omlyclo is interchangeable with Xolair to treat the same conditions: asthma, chronic rhinosinusitis, food allergy ...

Biosimilars marketed in the US typically have list prices 15% to 35% lower than ... sometimes force diabetics to ration their use of the drugs. Semglee's latest approval follows the publication ...

Celltrion has launched Steqeyma (ustekinumab-stba), its biosimilar of Stelara (ustekinumab), at list price at an 85% discount ...

However, budget documents claim that “the statutory distinction between biosimilars ... of these drugs in the US than other markets, such as Europe. The proposal is part of a long list of ...

The FDA has approved two new biosimilars of denosumab for all indications of the reference medications Prolia and Xgeva, ...

Omlyclo is used for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, ...